AN OPEN-LABEL, SINGLE-TREATMENT, SINGLE-PERIOD, SINGLE DOSE, CLINICAL PHASE 1 STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF LIVE MEASLES, MUMPS AND RUBELLA VACCINE, (MULTIPLE DOSE VIAL FORMULATION) OF M/s CADILA HEALTHCARE LTD., INDIA IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS UNDER FASTING CONDITIONS.
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Measles mumps and rubella virus vaccine (Primary)
- Indications Measles; Mumps; Rubella
- Focus Adverse reactions
- Sponsors Cadila Healthcare
- 30 Sep 2012 Status changed from recruiting to completed as reported by Clinical Trials Registry - India.
- 11 Sep 2012 New trial record